Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 432

1.

Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression.

Becker DJ, Iyengar AD, Punekar SR, Ng J, Zaman A, Loeb S, Becker KD, Makarov D.

Anticancer Res. 2019 May;39(5):2467-2473. doi: 10.21873/anticanres.13366.

PMID:
31092441
2.

Serum Prostate-Specific Antigen Level in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis.

Maleki-Hajiagha A, Razavi M, Rezaeinejad M, Sepidarkish M, Mehri A, Vesali S, Allameh Z.

Horm Metab Res. 2019 Apr;51(4):230-242. doi: 10.1055/a-0863-5779. Epub 2019 Apr 25.

PMID:
31022739
3.

Association between three genetic variants in kallikrein 3 and prostate cancer risk.

Ding WH, Ren KW, Yue C, Zou JG, Zuo L, Zhang LF, Bai Y, Okada A, Yasui T, Mi YY.

Biosci Rep. 2018 Nov 30;38(6). pii: BSR20181151. doi: 10.1042/BSR20181151. Print 2018 Dec 21.

4.

Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.

Gudmundsson J, Sigurdsson JK, Stefansdottir L, Agnarsson BA, Isaksson HJ, Stefansson OA, Gudjonsson SA, Gudbjartsson DF, Masson G, Frigge ML, Stacey SN, Sulem P, Halldorsson GH, Tragante V, Holm H, Eyjolfsson GI, Sigurdardottir O, Olafsson I, Jonsson T, Jonsson E, Barkardottir RB, Hilmarsson R, Asselbergs FW, Geirsson G, Thorsteinsdottir U, Rafnar T, Thorleifsson G, Stefansson K.

Nat Commun. 2018 Nov 8;9(1):4568. doi: 10.1038/s41467-018-06920-9.

5.

PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study.

Patel DN, Feng T, Simon RM, Howard LE, Vidal AC, Moreira DM, Castro-Santamaria R, Roehrborn C, Andriole GL, Freedland SJ.

Prostate Cancer Prostatic Dis. 2018 Jun;21(2):238-244. doi: 10.1038/s41391-018-0044-y. Epub 2018 May 23.

PMID:
29795141
6.

Discordant prostate specific antigen test results despite WHO assay standardization.

Boegemann M, Arsov C, Hadaschik B, Herkommer K, Imkamp F, Nofer JR, Gerß J, Albers P, Semjonow A.

Int J Biol Markers. 2018 Aug;33(3):275-282. doi: 10.1177/1724600818754750. Epub 2018 May 8.

PMID:
29734838
7.

Prostate-specific antigen associates with extensive lymph node invasion in high-risk prostate cancer.

Porcaro AB, Corsi P, Inverardi D, Sebben M, Tafuri A, Processali T, Mattevi D, De Marchi D, Pirozzi M, Cerruto MA, Amigoni N, Rizzetto R, Brunelli M, Siracusano S, Artibani W.

Tumori. 2018 Aug;104(4):307-311. doi: 10.1177/0300891618765567. Epub 2018 Apr 6.

PMID:
29714659
8.

Label-free photoelectrochemical aptasensor for tetracycline detection based on cerium doped CdS sensitized BiYWO6.

Han Q, Wang R, Xing B, Chi H, Wu D, Wei Q.

Biosens Bioelectron. 2018 May 30;106:7-13. doi: 10.1016/j.bios.2018.01.051. Epub 2018 Jan 31.

PMID:
29414091
9.

Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer.

Nordström T, Akre O, Aly M, Grönberg H, Eklund M.

Prostate Cancer Prostatic Dis. 2018 Apr;21(1):57-63. doi: 10.1038/s41391-017-0024-7. Epub 2017 Dec 19.

PMID:
29259293
10.

Superwettable microchips with improved spot homogeneity toward sensitive biosensing.

Chen Y, Xu LP, Meng J, Deng S, Ma L, Zhang S, Zhang X, Wang S.

Biosens Bioelectron. 2018 Apr 15;102:418-424. doi: 10.1016/j.bios.2017.11.036. Epub 2017 Nov 21.

PMID:
29175217
11.

Detection of early stage prostate cancer by using a simple carbon nanotube@paper biosensor.

Ji S, Lee M, Kim D.

Biosens Bioelectron. 2018 Apr 15;102:345-350. doi: 10.1016/j.bios.2017.11.035. Epub 2017 Nov 10.

PMID:
29172142
12.

Trajectories of prostate-specific antigen after treatment for prostate cancer.

Wu Z, Aslan M, Lin H, Ko J, Radhakrishnan K, Wells CK, Uchio E, Concato J.

J Investig Med. 2018 Apr;66(4):768-772. doi: 10.1136/jim-2017-000627. Epub 2017 Nov 22.

PMID:
29170243
13.
14.

Mutations in the prostate specific antigen (PSA/KLK3) correlate with male infertility.

Gupta N, Sudhakar DVS, Gangwar PK, Sankhwar SN, Gupta NJ, Chakraborty B, Thangaraj K, Gupta G, Rajender S.

Sci Rep. 2017 Sep 11;7(1):11225. doi: 10.1038/s41598-017-10866-1.

15.

Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients.

Logozzi M, Angelini DF, Iessi E, Mizzoni D, Di Raimo R, Federici C, Lugini L, Borsellino G, Gentilucci A, Pierella F, Marzio V, Sciarra A, Battistini L, Fais S.

Cancer Lett. 2017 Sep 10;403:318-329. doi: 10.1016/j.canlet.2017.06.036. Epub 2017 Jul 8.

PMID:
28694142
16.

PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study.

Bosso D, Pagliuca M, Sonpavde G, Pond G, Lucarelli G, Rossetti S, Facchini G, Scagliarini S, Cartenì G, Daniele B, Morelli F, Ferro M, Puglia L, Izzo M, Montanaro V, Bellelli T, Vitrone F, De Placido S, Buonerba C, Di Lorenzo G.

Medicine (Baltimore). 2017 Jun;96(24):e6817. doi: 10.1097/MD.0000000000006817.

17.

Chronic Periodontitis Does Not Impact Serum Levels of Prostate-specific Antigen.

Kruck S, Hennenlotter J, Amend B, Geiger M, Filipova E, Neumann T, Stühler V, Schubert T, Todenhöfer T, Rausch S, Huettig F, Stenzl A, Bedke J.

Anticancer Res. 2017 Jun;37(6):3163-3167.

PMID:
28551659
18.

Genetic association between PSA-158G/A polymorphism and the susceptibility of benign prostatic hyperplasia: a meta-analysis.

Su XJ, Zeng XT, Fang C, Liu TZ, Wang XH.

Oncotarget. 2017 May 16;8(20):33953-33960. doi: 10.18632/oncotarget.15424. Review.

19.
20.

Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.

Rathkopf DE, Antonarakis ES, Shore ND, Tutrone RF, Alumkal JJ, Ryan CJ, Saleh M, Hauke RJ, Bandekar R, Maneval EC, de Boer CJ, Yu MK, Scher HI.

Clin Cancer Res. 2017 Jul 15;23(14):3544-3551. doi: 10.1158/1078-0432.CCR-16-2509. Epub 2017 Feb 17.

Supplemental Content

Support Center